

Effects of early enteral bovine colostrum supplementation on intestinal permeability in critically ill patients: a randomized, double-blind, placebo-controlled study

Ghazaleh Eslamian MS, PhD candidate ,  
Seyed Hossein Ardehali MD , Ahmad-Reza Baghestani PhD ,  
Zahra Vahdat Shariatpanahi MD, PhD

PII: S0899-9007(18)30518-5  
DOI: <https://doi.org/10.1016/j.nut.2018.10.013>  
Reference: NUT 10352

To appear in: *Nutrition*

Received date: 17 June 2018  
Revised date: 27 September 2018  
Accepted date: 10 October 2018

Please cite this article as: Ghazaleh Eslamian MS, PhD candidate , Seyed Hossein Ardehali MD , Ahmad-Reza Baghestani PhD , Zahra Vahdat Shariatpanahi MD, PhD , Effects of early enteral bovine colostrum supplementation on intestinal permeability in critically ill patients: a randomized, double-blind, placebo-controlled study, *Nutrition* (2018), doi: <https://doi.org/10.1016/j.nut.2018.10.013>



This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

- Colostrum bovinum supplementation is safe with gastrointestinal benefits.
- The effect of bovine colostrum on plasma endotoxin and zonulin levels was investigated in critically ill patients.
- After 10-d of supplementation, bovine colostrum was found to decrease plasma endotoxin and zonulin levels.
- Bovine colostrum supplementation may have beneficial effects on intestinal permeability.

ACCEPTED MANUSCRIPT

# Effects of early enteral bovine colostrum supplementation on intestinal permeability in critically ill patients: a randomized, double-blind, placebo-controlled study

Ghazaleh Eslamian<sup>1</sup>, Seyed Hossein Ardehali<sup>2</sup>, Ahmad-Reza Baghestani<sup>3</sup>, Zahra Vahdat Shariatpanahi<sup>4\*</sup>

<sup>1</sup>MS, PhD candidate, Student Research Committee, Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>2</sup>MD, Department of Anesthesiology and Critical Care, Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>3</sup>PhD, Department of Biostatistics, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>4</sup>MD, PhD, Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran

\*Corresponding author. No 7, West Arghavan St., Farahzadi Blvd., Sanat Sq., Tehran, Iran.

Zip Code: 1981619573, P.O.Box: 19395-4741

Tel: +98 21 22360658, Fax: +98 2122360657, E-mail: nutritiondata@yahoo.com

**Funding sources:** This study is financially supported by National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

This trial was registered at <http://www.clinicaltrials.gov> as NCT03186716

**Conflicts of interest:** The authors have disclosed that they do not have any potential conflicts of interest.

Running Title: Colostrum and Intestinal Permeability

## Abstract

**Objectives:** In this study, we sought to investigate the effect of early enteral bovine colostrum supplementation on intestinal permeability in ICU-hospitalized patients.

**Methods:** A total of 70 ICU-hospitalized adult patients were randomly assigned to receive a bovine colostrum supplement or placebo according to the stratified blocked randomization by age and admission category. Plasma endotoxin and zonulin concentrations were measured on days 5 and 10 of intervention.

**Results:** Out of 70 participants, 32 patients in the colostrum group and 30 patients in the control group were included in the final analysis of the outcomes. Plasma endotoxin concentration decreased significantly in the colostrum group at the 10th days ( $P < 0.05$ ). Furthermore, plasma levels of zonulin reduced in the colostrum group significantly compared with the placebo group ( $P < 0.001$ ). The incidence of diarrhea was significantly lower in colostrum group than in control group ( $P = 0.02$ ).

**Conclusions:** Our results provide evidence that bovine colostrum supplementation may have beneficial effects on intestinal permeability and gastrointestinal complications in ICU-hospitalized patients. Further studies are needed to investigate the exact mechanism of action of these effects.

**Keywords:** colostrum, zonulin, endotoxin, diarrhea, intensive care unit, tube feeding

## Introduction

The gastrointestinal (GI) epithelium functions as an immunological barrier against luminal penetration by toxins, allergens, and pathogens [1]. This barrier function can be impaired by physical stress due to critical illness [2]. Moreover, the disruption of the specialized junctional complexes, called tight junctions, plays a crucial role in bacterial translocation and nosocomial infections [1]. These infections are commonly reported in the intensive care unit (ICU) and seem to be related to a gut-barrier malfunction in critically ill patients [2]. The overall function of transport through the intestinal epithelial paracellular route was assessed by non-invasive techniques including fractional urinary excretion of orally ingested probes, circulating the anti-flagellin and anti-lipopolysaccharide immunoglobulins, and circulating the zonulin level [3].

Colostrum is the initial milk produced by the mammary glands of mammals during the first few postpartum days. This liquid is particularly rich in biologically active growth factors such as growth hormone, insulin growth-like factors, epidermal growth factors, transforming growth factor- $\beta$ , and platelet-derived growth factor. Besides, it contains immunoglobulins, antimicrobial peptides, and macro- and micronutrients [4]. Colostrum bovinum has been shown to successfully protect or repair the intestinal barrier in both human and animal studies. Besides, it is useful for the treatment of a wide variety of GI conditions including inflammatory bowel disease, intense physical activity, nonsteroidal anti-inflammatory drug-induced gut injury, and chemotherapy-induced mucositis [5]. This efficacy of bovine colostrum in reducing the intestinal permeability may be attributed to a direct effect on maintenance of tight junctions in epithelial cells [6]. However, it has to be noted that the results from different studies are not always consistent and need further clarification. Despite the studies conducted on this subject, our current understanding of the impact of colostrum on intestinal permeability in critically ill patients is still limited.

We hypothesized co-administration of early enteral formula with bovine colostrum stimulates gut function and decreases intestinal permeability in critically ill patients. Therefore, to evaluate this hypothesis, a double blind, randomized, placebo-controlled clinical trial was established to determine effects of early enteral bovine colostrum supplementation on intestinal permeability in ICU-hospitalized patients.

## **Methods**

### **Recruitment and Eligibility Screening**

Critically ill patients were identified and recruited between June 2017 and March 2018 from general ICU of a university hospital in Tehran, Iran. Since we did not find a related study to our objective, a true power calculation was not applicable. Thus, we conducted a small pilot study in order to get the estimates needed to do a proper sample size calculation. Eligible patients or their legal representatives were informed about the study procedures by intensivists' specialist of critical care medicine. Eligible patients or their legal representatives signed an informed consent form after a full review of the inclusion and exclusion criteria and explaining the risks and benefits of the study. The study was approved by the related ethics committee in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Consecutive adult patients (>18 years old) meeting the following inclusion criteria were enrolled: start of study intervention within 48 hours after ICU admission; receiving enteral nutrition for at least 72 hours aiming for full enteral nutrition and receiving at least 80% of the enteral formula during the first 48 hours; and submitting written informed consent by themselves or their legal representative. Patients were also excluded for one or more of the following criteria: >24 hours from admission to the ICU; requiring other specific enteral nutrition (EN) for medical reason such as renal or liver failure; death or discharge before day 5; having any absolute contra-indication to receive EN; pregnant patients or lactating with the intent to breastfeed; body mass index (BMI) less than

18 kg/m<sup>2</sup> or greater than 40 kg/m<sup>2</sup>; not being in ICU for more than 48 hours due to imminent death; history of allergy or intolerance to the study product components; and enrollment or planned enrollment in a related ICU interventional study. Subject participation in the study was prematurely discontinued in the following situations: further participation was a health risk for the patient; a subject or legal representative who gave informed consent decided to resign from further participation in the study; and a patient might require a hospital transfer.

### **Study Design and Interventions**

The current study was a randomized, double-blind, placebo-controlled trial. At the first visit, patients who fulfilled the described criteria were randomly assigned to receive enteral formula plus 20 g/day bovine colostrum powder or isocaloric enteral formula plus maltodextrin for 10 days using a computer-generated randomization. Randomization was stratified by age (18-65 and  $\geq 65$  years) and admission category (medical, surgical, and trauma). Commercial enteral formula –ENTERA Meal (54.6% carbohydrate, 14% protein, and 31.6% fat) and maltodextrin were provided by Karen Pharma & Food Supplement, Co, Tehran, Iran. The bovine colostrum was supplied by Neovite, UK, London. The energy content was approximately 311.5 kJ (74.4 kcal) per 20 g (i.e., 80% protein, 9% carbohydrate (lactose), and 1.8% fat). Subjects, investigators, staffs, and outcome assessors were masked to the treatment assignment until the end of the study. There were no identifiable co-interventions associated with our intervention. Details about the recruitment, randomization, and follow-up of the current study are presented in the study flow diagram (Fig. 1).

### **Administration of Intervention**

The administration of all study products was initiated within 48 hours after admission at the ICU and ended at discharge from the ICU or at end of the study (Day 10). The study intervention consists of enteral colostrum 20g/day vs. isocaloric maltodextrin control

delivered enterally. The supplements were administered three times per day. Planned enteral tube feeding was initiated after stabilizing the hemodynamic condition of each patient. The enteral route (nasogastric or gastrostomy) chosen for a patient was at the discretion of the treating physician according to the patient's clinical condition. The volume (mL) of intermittent tube feeding was determined based on the calorie needs and tolerance of patients by starting from 50 mL. Through the first 24 hours, if the patient could tolerate the feeding, it was increased by 50 to 100 mL until the goal volume was reached. The supplements were administered three times a day. All patients were fed according to the last revision of American Society for Parenteral and Enteral Nutrition guideline [7]. General recommended energy and protein intakes for critically ill patients – based on weight and metabolic condition – were 25-30 kcal/kg and 1.2-2 g/kg, respectively. According to our calculation, if a patient had required an extra amount of protein, modular protein supplements would have been added to the enteral formula to increase the protein intakes. The volume and calorie intake were recorded on a daily basis. The volume ratio (VR) was calculated to determine the efficacy of daily nutritional administration:  $VR (\%) = (\text{volume administered} / \text{volume prescribed}) \times 100$ .

## Procedures

Each patient's age, sex, smoking behavior, length, medical history, pre-existing conditions, medication, and nutritional supplements use, enteral route, feeding regimen, date of hospital and ICU admission, and diagnosis for ICU admission were recorded at the screening visit. The Acute Physiology and Chronic Health Evaluation (APACHE II)[8], Sequential Organ Failure Assessment (SOFA) score [9], and Nutrition Risk score in the Critically Ill (NUTRIC)[10] were determined over the first 24 hours after admission at the ICU. From the start of feeding the study product until day 10, adverse events, GI intolerance, the net amount of tube feeding intake, and occurrence of sepsis were assessed on a daily basis. Venous blood



samples were drawn at baseline within 2 hours before the start of intervention and between 7 and 9 a.m. on day 5 and day 10 for laboratory data. Blood samples were collected in EDTA-containing tubes and plasma was obtained by centrifugation at 3,000 rpm for 10 minutes at 4°C. Plasma samples were snap-frozen and stored in small aliquots at -80°C until the laboratory analysis.

### **Primary and Secondary Outcomes**

Plasma endotoxin concentration and plasma zonulin concentration were the primary outcome measures. Plasma concentrations of endotoxin were measured by a commercially available quantitative chromogenic endpoint Limulus Amebocyte Lysate QCL-1000 kit (Lonza, Walkersville, MD). Zonulin levels were measured in plasma by enzyme-linked immunosorbent assay (Immundiagnostik, Bensheim, Germany). All assays were performed according to the respective manufacturer's recommendation and the tests were carried out in duplicate. Secondary outcomes included mortality at ICU, length of stay (LOS) in ICU, and the incidence of sepsis according to the American College of Chest Physicians and the Society of Critical Care Medicine [11], and the incidence of GI complications including abdominal distention, vomiting, diarrhea, and constipation.

### **Statistical Analysis**

The analyses in this work were performed using the SPSS software (version 20; Chicago, IL, USA). Data were presented as frequencies and percentages, means, and 95% confidence intervals (CIs) or standard deviations, or medians and interquartile ranges (IQR), when appropriate. Chi-square or Fisher's exact tests were used to examine the significance of the differences in the distribution of categorical variables. As most of the variables were highly skewed and not normally distributed, continuous variables were analyzed using the Mann-Whitney test for the between-group comparisons and the Wilcoxon signed rank test for the

within-group comparisons. According to the CONSORT guidelines, both intention-to-treat (ITT) and per-protocol analyses were done for all planned outcomes in order to interpret the effect of our intervention. The data are reported according to the ITT principle. Missing measurements of the primary and secondary outcome measures were imputed using the regression method. Means and 95% CIs for changes from baseline in plasma endotoxin concentration and plasma zonulin concentration were compared on days 5 and 10 using the ANCOVA. All hypothesis tests were two-tailed with a  $P < 0.05$  statistical significance.

## Results

### Recruitment and Follow-up

In this work, 70 patients were randomly assigned to two groups: colostrum ( $n=35$ ) and control ( $n=35$ ). The flowchart depicting the patient screening, enrollment, and retention by treatment group is shown in Fig. 1. In the colostrum group, one patient died between 5th and 10th days and one patient was withdrawn by physician between 5th and 10th days. In the control group, four patients died between 5th and 10th days and one patient transferred to another hospital between 5th and 10th day. Thus, we had the baseline and 5th day data for two patients in the colostrum group and for five patients in the control group and missing measurements were imputed for these patients. Finally 32 patients in the colostrum group and 30 patients in the control group were included in the final ITT analysis. Baseline characteristics of participants completing the study were not significantly different from those who did not complete the protocol of the study ( $P > 0.05$  for all variables).

### Baseline Characteristics of the Patients

The baseline clinical and demographic characteristics of both groups are presented in Table 1. It is of note that the randomized groups shared similar baseline characteristics. The study participants had a mean age of 62 years and 56% ( $n = 35$ ) of them were male. The results

obtained from the analysis of feeding details are presented in Table 2. There was no significant difference in terms of duration of study product administration, the time of starting nutritional support, the energy intake, the protein intake or total volume of study product administered.

### Primary Outcome

The baseline median (IQR) plasma zonulin of participants was 5.5(3.3-8.1) and 4.9(3.4-7.5) ng/mL in colostrum and control groups, respectively, demonstrating no statistically significant difference ( $P = 0.855$ ). The plasma zonulin and endotoxin concentrations on days 1, 5, and 10 are shown in Table 3. Early enteral bovine colostrum supplementation produced a significant difference in the plasma levels of zonulin results obtained before and after the supplementation period. At the end of day 10 of the treatment period, the plasma zonulin concentration decreased in the colostrum group and increased in the control group and led to a statistically significant difference ( $p < 0.001$ ) when comparing the post-intervention to baseline changes between two groups. The change in the zonulin concentration on days 5 and 10 (Table 3) showed a statistically significant difference between those treated with colostrum or placebo after the adjustment for albumin and energy intake ( $P < 0.001$ ). The baseline plasma levels of endotoxin of the two groups were similar ( $P = 0.297$ ). Colostrum supplementation produced a significant decrease in the plasma endotoxin concentration on days 5 and 10. Comparing the baseline and end of the study results revealed a significant decrease in the plasma levels of endotoxin within the colostrum group ( $P = 0.007$ ). The change in the plasma endotoxin concentration (Table 3) showed a statistically significant difference ( $P = 0.01$ ) between those treated with colostrum or placebo on days 5 and 10 after the adjustment for albumin and energy intake.

### Secondary Outcomes

Table 4 shows the analysis of the incidence of gastrointestinal complication. Neither placebo nor colostrum supplementation produced a significant difference in the incidence of abdominal distention, vomiting, and constipation. The incidence of diarrhea was significantly lower in colostrum group (9%) than the control group (33%).

There were not any statistically significant differences in mortality at ICU between the colostrum group (12%, 95%CI; 3-24%) and the control group (17%, 95%CI; 6-30%;  $P=0.642$ ). There were no statistically significant differences for the incidence of new severe sepsis between groups. Overall, 6% of those in the colostrum group (95%CI; 0-16 %) versus 10% in the control group (95% CI, 0-21%;  $P=0.588$ ) had new severe sepsis. The median (IQR) LOS in ICU was 10 (8-15) and 17 (8-30) days for the colostrum group and the control group, respectively, indicating a statistically significant difference ( $P=0.045$ ).

### **Adverse events**

Most patients tolerated enteral nutrition and achieved the planned caloric goal within the first 2 days of intervention. Enteral bovine colostrum was generally well tolerated and none of the patients completing the study had any serious clinical adverse reactions.

### **Discussion**

To our knowledge, this study is the first randomized double blind clinical trial that evaluates the effects of early enteral bovine colostrum supplementation on intestinal permeability in ICU-hospitalized patients. Our results showed that intestinal permeability as assessed by the plasma endotoxin and zonulin concentrations was improved after a short period of colostrum-supplemented enteral feedings. Moreover, administration of the bovine colostrum had beneficial effects on diarrhea and LOS in ICU; however, it did not affect any other gastrointestinal complications, mortality, and severe sepsis.

Intestinal permeability is a key feature of gut barrier function and can be assessed through enteral administration of non-digestible markers, including sugars, radioisotopes, and polyethylene glycols [12]. In most previous clinical trials in critical care, the dual sugar absorption tests were used as gut permeability assessment [13]; however, there are no standardized protocols for this purpose [3]. Furthermore, conducting these tests for ICU-hospitalized patients are challenging considering the time of urine collection and fasting time [3]. Thus, we used the plasma concentration of endotoxin, lipopolysaccharide (LPS) constituents of the outer membrane of gram-negative bacteria [14], and the plasma concentration of zonulin as a master regulator of intercellular tight gap junctions [15]. In our study, colostrum bovinum supplementation was safe and effective in decreasing the plasma endotoxin compared with the control group. In agreement with our study, Bölke et al. [16] found that the oral application of immunoglobulin-enriched colostrum milk (lactobin 56 g/day) for 3 days before abdominal surgery reduced perioperative endotoxemia. In contrast to our study, Bölke et al. [17] showed the enteral application of 42 g of bovine colostrum milk per day for 2 days preoperatively failed to curtail perioperative endotoxemia in patients undergoing coronary bypass surgery. The exact mechanisms by which colostrum might influence endotoxemia are unknown, but studies suggest that their influence is mediated by lactoferrin, which is able to bind the lipid A part of the LPS-molecules to prevent their uptake into the systemic circulation [18]. Our results showed that the bovine colostrum supplementation was able to reduce the plasma zonulin level. To our knowledge, zonulin was not considered as an outcome in previous clinical trials in ICU-hospitalized patients. Greis et al [19] demonstrated that patients at ICU admission had higher serum concentrations of zonulin-1. A recent study has reported that 20 days of bovine colostrum supplementation can reduce stool concentrations of zonulin in athletes [20]. Bovine colostrum may also have a beneficial role in athletes [20-22] and some patients [23], in whom intestinal permeability

risks due to various pathologies, and help restore gut status after use of antibiotics or nonsteroidal anti-inflammatory drugs (NSAIDs), both of which can increase intestinal permeability [24].

The majority of ICU patients have at least one gastrointestinal symptom during their ICU stay [25]. In our study, there was no discernible difference in the secondary outcomes relating to the incidence of GI complications except diarrhea. Our results have shown that enteral bovine colostrum supplements lower the incidence of diarrhea. This result is consistent with few studies that have investigated the effects of immunoglobulin-enriched colostrum milk on diarrhea due to protozoal pathogens in HIV-infected patients [18]. Tacket et al. [26] showed that hyperimmune bovine colostrum significantly reduced the incidence of diarrhea resulting from challenge with *S. flexneri* in healthy adult volunteers. Otto et al. [27] along with the mentioned researchers demonstrated that a tablet formulation of hyperimmune bovine colostrum was significantly more effective in protecting healthy adult volunteers against the development of diarrhea caused by *Escherichia coli*. Bovine colostrum has been reported to positively influence infective diarrhea in both human and animal studies [5]. Previous clinical trials on the use of bovine colostrum in children have also demonstrated a significant reduction in the number of diarrhea episodes [18, 23]. Possible mechanisms by which colostrum might improve diarrhea include the effect of increased mucosal resistance caused by epidermal growth factor and lactoferrin [27-29].

The principal goal of implementing ICU was to decrease mortality in critically ill patients [30]. In addition to mortality, assessing another clinical outcome could help define the usefulness of an intervention. After 10 days of our intervention, LOS in ICU group was significantly reduced in the colostrum compared with the control. However, no effect on ICU-acquired sepsis and mortality was noted in our study.

The most important strength of this study was the stratified randomization of patients. Our study has certain limitations. It was a single-center trial with a small sample size. Body weight was recorded according to the patients' or relative's statement at enrollment or based on recent patient file information. The diversity of critically ill patients makes it difficult to select a homogenous population with minimal variation in outcome parameters. The ICU length of stay of patients also differs highly from the consequence that some patients are being tube fed for only a few days and others more than a month. Another limitation is that the participants were not followed up further to assess the sustainability of the findings obtained after the termination of intervention. These findings should be confirmed in future studies.

In conclusion, this clinical trial was among the first ones that found preliminary evidence of beneficial effects of bovine colostrum supplementation on intestinal permeability, LOS in ICU, and diarrhea in ICU-hospitalized patients. On this conclusion, we suggest that it may be feasible and justifiable to use bovine colostrum as a supplement with various doses in further studies to confirm our finding. To date, there is little consensus on the effect of colostrum on clinical outcomes in critically ill patients. So, future randomized placebo-controlled trials are needed to investigate the mechanism of action of these effects.

### **Acknowledgements**

This study is a part of a PhD thesis in nutrition sciences, supported by a grant from the National Nutrition and Food Technology Research Institute of Shahid Beheshti University of Medical Sciences, Tehran, Iran. The authors are indebted to the general ICU of Shohadaye Tajrish Hospital in Tehran, Iran. They also thank the patients who participated in this study and the ICU personnel for their assistance; indeed, without their collaboration the study would not have been possible. None of the authors has any conflicts of interest to declare.

### **Statement of Authorship**

The authors' contributions are as follows: G.E. and Z.S. conceptualized and designed the study and wrote the manuscript; G.E. and A.B. analyzed data; G.E. and H.A. collected data; G.E. and Z.S. interpreted the data, provided professional comments; H.A. and A.B. critically revised the manuscript for intellectual content and data accuracy; and G.E. and Z.S. had responsibility for final content. All of the authors read and approved the final manuscript.

### **Conflict of Interest Statement**

The authors have disclosed that they do not have any potential conflicts of interest.

### **References**

- [1] Scaldaferri F, Pizzoferrato M, Gerardi V, Lopetuso L, Gasbarrini A. The gut barrier: new acquisitions and therapeutic approaches. *J Clin Gastroenterol* 2012;46 Suppl:S12-7.
- [2] MacFie J. Bacterial Translocation, Gut Barrier Function and Nutritional Support. *Surgery* (Oxford). 2002;20:i-ii.
- [3] Galipeau HJ, Verdu EF. The complex task of measuring intestinal permeability in basic and clinical science. *Neurogastroenterology and motility : the official journal of the European Neurogastroenterol Motil* 2016;28:957-65.
- [4] Aunsholt L, Jeppesen PB, Lund P, Sangild PT, Ifaoui IB, Qvist N, et al. Bovine colostrum to children with short bowel syndrome: a randomized, double-blind, crossover pilot study. *JPEN J Parenter Enteral Nutr* 2014;38:99-106.
- [5] Playford RJ, Macdonald CE, Johnson WS. Colostrum and milk-derived peptide growth factors for the treatment of gastrointestinal disorders. *Am J Clin Nutr* 2000;72:5-14.
- [6] Prosser C, Stelwagen K, Cummins R, Guerin P, Gill N, Milne C. Reduction in heat-induced gastrointestinal hyperpermeability in rats by bovine colostrum and goat milk powders.. *J Appl Physiol* (1985)2004;96:650-4.



- [7] McClave SA, Taylor BE, Martindale RG, Warren MM, Johnson DR, Braunschweig C, et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr 2016;40:159-211.
- [8] Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
- [9] Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10.
- [10] Heyland DK, Dhaliwal R, Jiang X, Day AG. Identifying critically ill patients who benefit the most from nutrition therapy: the development and initial validation of a novel risk assessment tool. Crit Care 2011;15:R268.
- [11] Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-55.
- [12] Wang L, Llorente C, Hartmann P, Yang AM, Chen P, Schnabl B. Methods to determine intestinal permeability and bacterial translocation during liver disease. J Immunol Methods 2015;421:44-53.
- [13] De-Souza DA, Greene LJ. Intestinal permeability and systemic infections in critically ill patients: effect of glutamine. Crit Care Med 2005;33:1125-35.
- [14] van Deventer SJ, ten Cate JW, Tytgat GN. Intestinal endotoxemia. Clinical significance. Gastroenterology 1988;94:825-31.

- [15] Sturgeon C, Fasano A. Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases. *Tissue barriers* 2016;4:e1251384.
- [16] Bolke E, Jehle PM, Hausmann F, Daubler A, Wiedeck H, Steinbach G, et al. Preoperative oral application of immunoglobulin-enriched colostrum milk and mediator response during abdominal surgery. *Shock* 2002;17:9-12.
- [17] Bolke E, Orth K, Jehle PM, Schwarz A, Steinbach G, Schleich S, et al. Enteral application of an immunoglobulin-enriched colostrum milk preparation for reducing endotoxin translocation and acute phase response in patients undergoing coronary bypass surgery--a randomized placebo-controlled pilot trial. *Wien Klin Wochenschr* 2002;114:923-8.
- [18] Struff WG, Sprotte G. Bovine colostrum as a biologic in clinical medicine: a review--Part II: clinical studies. . *Int J Clin Pharmacol Ther* 2008;46:211-25.
- [19] Greis C, Rasuly Z, Janosi RA, Kordelas L, Beelen DW, Liebrechts T. Intestinal T lymphocyte homing is associated with gastric emptying and epithelial barrier function in critically ill: a prospective observational study. *Crit Care* 2017;21:70.
- [20] Hałasa M, Maciejewska D, Bańkiewicz-Hałasa M, Machaliński B, Safranow K, Stachowska E. Oral Supplementation with Bovine Colostrum Decreases Intestinal Permeability and Stool Concentrations of Zonulin in Athletes. *Nutrients* 2017;9.
- [21] Marchbank T, Davison G, Oakes JR, Ghatei MA, Patterson M, Moyer MP, et al. The nutraceutical bovine colostrum truncates the increase in gut permeability caused by heavy exercise in athletes. *Am J Physiol Gastrointest Liver Physiol* 2011;300:G477-84.
- [22] Buckley JD. Bovine colostrum: Does it improve athletic performance? *Nutrition* (Burbank, Los Angeles County, Calif). 2002;18:776-7.
- [23] Rathe M, Muller K, Sangild PT, Husby S. Clinical applications of bovine colostrum therapy: a systematic review. *Nutr Rev* 2014 2014;72:237-54.

- [24] Playford RJ, MacDonald CE, Calnan DP, Floyd DN, Podas T, Johnson W, et al. Co-administration of the health food supplement, bovine colostrum, reduces the acute non-steroidal anti-inflammatory drug-induced increase in intestinal permeability. *Clin Sci (Lond)* 2001;100:627-33.
- [25] Reintam A, Parm P, Kitus R, Kern H, Starkopf J. Gastrointestinal symptoms in intensive care patients. *Acta Anaesthesiol Scand* 2009;53:318-24.
- [26] Tacket CO, Binion SB, Bostwick E, Losonsky G, Roy MJ, Edelman R. Efficacy of bovine milk immunoglobulin concentrate in preventing illness after *Shigella flexneri* challenge. *Am J Trop Med Hyg* 1992;47:276-83.
- [27] Otto W, Najnigier B, Stelmasiak T, Robins-Browne RM. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused by enterotoxigenic *Escherichia coli* in volunteers. *Scand J Gastroenterol Suppl* 2011;46:862-8.
- [28] van Hooijdonk AC, Kussendrager KD, Steijns JM. In vivo antimicrobial and antiviral activity of components in bovine milk and colostrum involved in non-specific defence. *Br J Nutr* 2000;84 Suppl 1:S127-34.
- [29] Stelwagen K, Carpenter E, Haigh B, Hodgkinson A, Wheeler TT. Immune components of bovine colostrum and milk. *J Anim Sci* 2009;87:3-9.
- [30] Gaudry S, Messika J, Ricard JD, Guillo S, Pasquet B, Dubief E, et al. Patient-important outcomes in randomized controlled trials in critically ill patients: a systematic review. *Ann Intensive Care* 2017;7.

**Table 1**  
**Baseline characteristics of the study participants**

Characteristic	Colostrum group n=32	Control group n=30	P Value
Age, yr, median (IQR)	64 (52-70)	66 (58-71)	0.401*
Sex, No. (%)			0.290**
Male	16 (50)	19 (63)	
Female	16 (50)	11 (37)	
Admission category, No (%)			0.508**
Medical	15 (47)	14 (47)	
Surgical	8 (25)	11 (36)	
Trauma	9 (28)	5 (17)	
Admission scores, median (IQR)			
APACHE-II	23 (19-39)	24 (18-38)	0.983*
NUTRIC	5 (4-6)	5 (4-6)	0.913*
SOFA	6 (5-7)	6 (5-7)	0.742*
Baseline blood levels, median (IQR)			
Albumin, g/dL	2.8 (1.9-3.3)	2.5 (1.7-4.3)	0.789*

\*Mann-Whitney test

\*\*X<sup>2</sup> test or Fisher exact test

APACHE-II, Acute Physiology and Chronic Health Evaluation; ICU, intensive care unit; IQR, interquartile range; NUTRIC, Nutrition Risk in the Critically Ill; SOFA, Sequential Organ Failure Assessment

**Table 2**  
**Feeding details of the study participants**

Enteral feeding administration	Colostrum group n=32	Control group n=30	P Value
Time from ICU admission to study EN start, median (IQR), h	29 (25-35)	29 (24-35)	0.762*
Duration of administration, median (IQR), d	10 (8-10)	10 (9-10)	0.879*
Mean planned energy intake, median (IQR), Kcal/d	1479 (1400-1547)	1488 (1386-1575)	0.773*
Mean planned protein intake, median (IQR), g/d	65 (62-69)	64 (61-68)	0.632*
VR at Day 1, median (IQR), %	87 (85-92)	85 (83-93)	0.170*
VR at Day 5, median (IQR), %	91 (87-96)	89 (85-92)	0.063*
VR at Day 10, median (IQR), %	93 (85-98)	90 (83-94)	0.200*
Mean energy intake, median (IQR), Kcal/d	1350 (1254-1400)	1317 (1250-1358)	0.268*
Mean protein intake, median (IQR), g/d	60 (56-61)	57 (55-60)	0.124*
Patients with supplemental parenteral nutrition, No (%)	4 (12.5)	4 (13.3)	0.922**

\*Mann-Whitney test

\*\*X<sup>2</sup> test

EN, enteral nutrition; ICU, intensive care unit; IQR, interquartile range; VR, volume ratio

**Table 3**  
**Intestinal permeability outcomes at baseline, day 5 and day 10 by treatment group**

	Colostrum group n=32	Control group n=30	P Value
Plasma endotoxin concentration (EU/mL)			
Baseline, median (IQR)	0.59 (0.45-0.78)	0.56 (0.45-0.69)	0.607*
Day 5, median (IQR)	0.35 (0.13-0.50)	0.46 (0.29-0.55)	0.066*
Day 10, median (IQR)	0.15 (0.10-0.39)	0.57 (0.40-0.66)	< 0.001**
Mean changes in Day 5 from baseline(95% CIs)	-0.27 (-0.34, -0.20)	-0.15 (-0.22, -0.08)	0.018**
Mean changes in Day 10 from baseline(95% CIs)	-0.40 (-0.48, -0.27)	-0.04 (-0.10, 0.03)	< 0.001**
Plasma zonulin concentration (ng/mL)			
Baseline, median (IQR)	5.5 (3.3-8.1)	5.0 (3.4-7.5)	0.855*
Day 5, median (IQR)	4.1 (3.1-7.0)	6.1 (4.5-7.7)	0.018*
Day 10, median (IQR)	3.5 (2.9-5.9)	7.2 (5.7-8.4)	< 0.001**
Mean changes in Day 5 from baseline(95% CIs)	-0.97 (-1.47, -0.47)	0.69 (0.24, 1.14)	< 0.001**
Mean changes in Day 10 from baseline(95% CIs)	-1.79 (-2.55, -1.03)	1.72 (1.05, 2.39)	< 0.001**


\* Mann-Whitney test

\*\* Based on an ANCOVA model that regressed changes from baseline on treatment group, baseline value of the outcome, albumin and energy intake

**Table 4**  
**Comparison of gastrointestinal complication diagnosed after initiation of intervention between groups**

Gastrointestinal complication, No (%)	Colostrum group n=32	Control group n=30	P Value*
Abdominal distention	7 (22)	8 (27)	0.660
Vomiting	2 (6)	2 (7)	0.947
Diarrhea	3 (9)	10 (33)	0.021
Constipation	6 (19)	10 (33)	0.190

\*  $\chi^2$  test, Fisher exact test



**Figure 1.** Flow chart depicting the study design